Radius Health announces positive top-line data from osteoporosis study

Radius Health (Nasdaq: RDUS) has announced positive top-line data from the first six months of the ACTIVExtend trial in postmenopausal osteoporosis.

The first six months of the Phase III ACTIVExtend trial were conducted in 1,139 subjects enrolled in the ACTIVE trial, who completed 18 months of treatment with either abaloparatide or placebo. Patients in the ACTIVE study were offered up to 24 additional months of treatment with ALN at a dose of 70mg per week.

The ACTIVExtend study showed that women did not experience new fractures when taking alendronate following 18 months of therapy with abaloparatide. The results show that abaloparatide could provide significant clinical benefit with reductions in the incidence of new vertebral, non-vertebral and clinical osteoporotic fractures.